Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H73NO16 |
| Molecular Weight | 848.0261 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 18 / 18 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]2[C@H](C)[C@@H](O[C@]3([H])O[C@H](C)C[C@@H]([C@H]3OC(=O)CCCC(O)=O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]2C
InChI
InChIKey=GMDGJSKLFNMCPF-UCYLELOBSA-N
InChI=1S/C42H73NO16/c1-14-28-42(10,52)35(48)23(4)32(47)21(2)19-40(8,51)37(59-39-34(27(43(11)12)18-22(3)54-39)57-30(46)17-15-16-29(44)45)24(5)33(25(6)38(50)56-28)58-31-20-41(9,53-13)36(49)26(7)55-31/h21-28,31,33-37,39,48-49,51-52H,14-20H2,1-13H3,(H,44,45)/t21-,22-,23+,24+,25-,26+,27+,28-,31+,33+,34-,35-,36+,37-,39+,40-,41-,42-/m1/s1
DescriptionSources: http://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Sources: http://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15808097http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment: Information about erythromycin ethylsuccinate is unavailable.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363135 |
14.0 nM [Kd] | ||
Target ID: CHEMBL2363135 |
|||
Target ID: CHEMBL2363135 |
14.0 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
| Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
| Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
| Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
| Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date1972 |
|||
| Curative | Davercin Approved UseFor the topical treatment of acne vulgaris |
|||
| Curative | Davercin Approved UseFor the topical treatment of pneumonia |
|||
| Curative | Davercin Approved UseIndicated for the treatment of bacterial endocarditis |
|||
| Curative | Davercin Approved UseUnknown |
|||
| Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
| Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
| Curative | E.E.S Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
| Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
|||
| Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date1965 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.44 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.99 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1161.5 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1386.1 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3544.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4096.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.48 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.31 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.8%) Sources: |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (14.6%) Sources: Abdominal pain (4.9%) |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Disc. AE: Epigastralgia, Nausea... AEs leading to discontinuation/dose reduction: Epigastralgia (grade 2-3, 2.5%) Sources: Nausea (grade 3, 3.3%) Vomiting (grade 2, 0.8%) |
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Other AEs: Akathisia, Diarrhea... Other AEs: Akathisia (below serious, 1 patient) Sources: Diarrhea (below serious, 1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Pancreatitis | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
|
| Pancreatitis | 5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
|
| Vomiting | 2.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
| Nausea | 14.6% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
| Abdominal pain | 4.9% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
| Vomiting | grade 2, 0.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
| Epigastralgia | grade 2-3, 2.5% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
| Nausea | grade 3, 3.3% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
| Akathisia | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
| Diarrhea | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| moderate [IC50 9.9 uM] | yes (co-administration study) Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin; Page: 10.0 |
|||
| yes [IC50 217 uM] | ||||
| yes [IC50 22.7 uM] | ||||
| yes [IC50 34 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
| yes | likely (co-administration study) Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=9 Page: 9.0 |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Use in pediatrics of a new form of erythromycin: erythromycin ethyl succinate]. | 1969 Mar 5 |
|
| A C-13 relaxation study on erythromycin A cyclic 11,12-carbonate. | 1978 May |
|
| Comparison of oral erythromycin ethylsuccinate and ciprofloxacin in the treatment of acute respiratory tract infections. | 1990 Oct |
|
| Drug-induced gallbladder disease. Incidence, aetiology and management. | 1992 Jan-Feb |
|
| [Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci]. | 1992 May |
|
| [In vitro activity of sparfloxacin against mycoplasmas]. | 1992 May |
|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| The effects of grapefruit juice on the pharmacokinetics of erythromycin. | 2001 Jan-Feb |
|
| Early and delayed effects of carboplatin on the blood system. | 2001 Nov |
|
| [Blueberry muffin baby: the pathogenesis of cutaneous extramedullary hematopoiesis]. | 2001 Nov |
|
| Synthesis of erythro and threo furanoid glycals from 1- and 2-phenylselenenyl-carbohydrate derivatives. | 2001 Nov 8 |
|
| Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. | 2001 Oct |
|
| [Orotic acid as a metabolic agent]. | 2002 |
|
| Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). | 2002 Aug |
|
| Stereoselective binding of 2-(4-biphenylyl)-3-substituted-3-hydroxypropionic acids on an immobilised human serum albumin chiral stationary phase. | 2002 Feb 25 |
|
| [Hormone level and metabolism of xenobiotics in rats with various phenotype of resistance to hypoxia]. | 2002 Jan-Feb |
|
| Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. | 2002 Jul |
|
| Dynamics of CD34+ progenitor cells following allogeneic bone marrow transplantation in Ph1+CML--an immunohistochemical study on 113 patients with sequential trephine biopsies. | 2002 Jun |
|
| Synthesis of (+)-aptosimon, a 4-oxofurofuran lignan, by erythro selective aldol condensation and stereoconvergent cyclization as the key reactions. | 2003 Apr |
|
| Effects of amphotericin B and caspofungin on histamine expression. | 2003 Aug |
|
| Effect of erythromycin on contractile response of uterine smooth muscle strips in non-pregnant rats. | 2003 Jan-Feb |
|
| Stereoselective biosynthesis of chloroarylpropane diols by the basidiomycete Bjerkandera adusta. | 2003 Jul |
|
| A highly chemoselective, diastereoselective, and regioselective epoxidation of chiral allylic alcohols with hydrogen peroxide, catalyzed by sandwich-type polyoxometalates: enhancement of reactivity and control of selectivity by the hydroxy group through metal-alcoholate bonding. | 2003 Mar 7 |
|
| Isolation and antimicrobial susceptibility of Aeromonas salmonicida in rainbow trout (Oncorhynchus mykiss) in turkey hatchery farms. | 2003 Sep |
|
| The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. | 2003 Sep 1 |
|
| Bitterness evaluation of medicines for pediatric use by a taste sensor. | 2004 Aug |
|
| Delayed Gastric Emptying in Functional Dyspepsia. | 2004 Aug |
|
| Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. | 2004 Dec |
|
| Local mechanisms underlying the regulatory effect of Kropanol on hemopoiesis during paradoxical sleep deprivation. | 2004 Feb |
|
| Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. | 2004 Feb |
|
| [3 + 2] Cycloreversion of bicyclo[m.3.0]alkan-3-on-2-yl-1-oxonium ylides to alkenyloxyketenes. Stereospecific aspect. | 2004 Feb 20 |
|
| Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids. | 2004 Feb 23 |
|
| Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. | 2004 Jul |
|
| Highly diastereoselective reductive coupling of 2-bromo-2,3,3,3-tetrafluoropropanamide with aldehydes promoted by triphenylphosphine-titanium(IV) isopropoxide. An efficient route to the synthesis of erythro-alpha-fluoro-alpha-(trifluoromethyl)-beta-hydroxy amides. | 2004 Jul 23 |
|
| Effect of mixing method on the mixing degree during the preparation of triturations. | 2004 Mar |
|
| Conformational study of a guaiacyl beta-O-4 lignin model compound by NMR. Examination of intramolecular hydrogen bonding interactions and conformational flexibility in solution. | 2004 Mar |
|
| Mechanism of beta-silyl diacyl peroxide decomposition: a mild and stereoselective synthesis of beta-silyl esters. | 2004 May 28 |
|
| Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. | 2004 Nov |
|
| Enantiomeric separation of racemic neolignans on chiralcel OD and determination of their absolute configuration with online circular dichroism. | 2004 Oct |
|
| Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats. | 2004 Sep |
|
| Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). | 2005 Aug |
|
| On the CH...Cu agostic interaction: chiral copper(II) compounds with ephedrine and pseudoephedrine derivatives. | 2005 Aug 14 |
|
| Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. | 2005 Jan |
|
| High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. | 2005 Jan |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Desensitization of the human motilin receptor by motilides. | 2005 Jun |
Patents
Sample Use Guides
Initial dose - 30 mg/kg, then 15 mg/kg every 12 hours.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L26Z5V0FQX
Created by
admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
|
PRIMARY | |||
|
53904-54-4
Created by
admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
|
PRIMARY | |||
|
72941564
Created by
admin on Fri Dec 15 15:46:23 GMT 2023 , Edited by admin on Fri Dec 15 15:46:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
